North West Anglia Foundation NHS Trusts’ Peterborough City Hospital implements the Genedrive® CYP2C19-ID Kit for routine clinical use
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that the Genedrive® CYP2C19-ID Kit has been implemented into the Hyperacute and Acute Stroke Units of Peterborough City Hospital Acute Stroke Centre for routine clinical use.
Hyperacute Stroke units (“HASUs”) and Acute Stroke Units (“AUs”) are part of the UK’s Integrated Stroke Delivery Network, where care typically covers the first 72 hours after admission, with the aim that every patient with acute stroke should gain rapid access to a stroke unit in under 4 hours, and receive an early multidisciplinary assessment1.
Peterborough City Hospital provides care to approximately 900 stroke patients per annum and is part of North West Anglia Foundation NHS Trust Acute Stroke Centre. The implementation seeks initially to provide genotype-guided optimisation of prescription of antiplatelet drugs to patients presenting with recurrent ischaemic strokes or transient ischaemic attack as well as to young stroke patients aged 18 to 55 within the North West Anglia NHS Foundation Trust Acute Stroke Centre region.
Dr Gino Miele, CEO of genedrive plc, said: “We are delighted with the successful implementation of our rapid CYP2C19 genotyping technology in Peterborough City Hospital, this represents a further milestone in our commercialisation strategy, which continues to strengthen our rapid pharmacogenetic positioning strategy in emergency care more broadly. We look forward to growing implementation of our CYP2C19 test in the UK NHS and internationally, enabling significant improvement of patient outcomes whilst also offering substantial resource savings to pressured healthcare systems.”
Professor Radim Licenik, Consultant Stroke Physician, Clinical Lead for Stroke Service and President of the Society of Czech & Slovak Doctors in the United Kingdom, said: “We are delighted to bring the benefit of this novel technology to Stroke patients in our region. Effective clinical management of neurologic stroke relies in part on optimising the efficacy of anti-platelets prescribed, and within a timeframe that is served only by rapid genetic testing technologies such as this. The implementation will help us to formulate a personalised optimal treatment plan for our stroke patients, that we hope will prevent future strokes and save lives.”
1. https://www.england.nhs.uk/wp-content/uploads/2021/05/stroke-service-model-may-2021.pdf
For further details please contact:
genedrive plc
+44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO
